Veru (NASDAQ:VERU – Get Rating) had its price target lifted by analysts at Brookline Capital Acquisition from $29.00 to $31.00 in a note issued to investors on Wednesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. Brookline Capital Acquisition’s price objective would suggest a potential upside of 114.53% from the company’s previous close.
A number of other equities analysts have also weighed in on VERU. Oppenheimer boosted their price target on shares of Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 12th. TheStreet raised shares of Veru from a “d+” rating to a “c” rating in a research note on Friday, April 29th. Zacks Investment Research cut shares of Veru from a “buy” rating to a “hold” rating in a report on Thursday, April 21st. Jefferies Financial Group increased their price target on shares of Veru from $33.00 to $55.00 in a research note on Friday, May 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Veru in a research note on Friday, May 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $32.17.
Shares of Veru stock traded down $1.15 during trading on Wednesday, hitting $14.45. 567,894 shares of the company’s stock were exchanged, compared to its average volume of 22,628,762. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -42.38 and a beta of -0.58. The business has a 50-day simple moving average of $8.54 and a 200-day simple moving average of $7.14. Veru has a 52-week low of $4.34 and a 52-week high of $17.50.
A number of institutional investors have recently made changes to their positions in VERU. BlackRock Inc. grew its stake in Veru by 3.8% in the 3rd quarter. BlackRock Inc. now owns 4,237,483 shares of the company’s stock valued at $36,146,000 after acquiring an additional 154,862 shares during the last quarter. Vanguard Group Inc. grew its stake in Veru by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 3,149,286 shares of the company’s stock valued at $15,212,000 after acquiring an additional 119,891 shares during the last quarter. State Street Corp grew its stake in Veru by 7.5% in the 1st quarter. State Street Corp now owns 1,163,926 shares of the company’s stock valued at $5,622,000 after acquiring an additional 80,978 shares during the last quarter. Geode Capital Management LLC grew its stake in Veru by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 1,083,324 shares of the company’s stock valued at $6,380,000 after acquiring an additional 14,144 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Veru by 9.3% in the 4th quarter. Nuveen Asset Management LLC now owns 807,839 shares of the company’s stock valued at $4,758,000 after acquiring an additional 68,520 shares during the last quarter. Institutional investors own 29.11% of the company’s stock.
About Veru (Get Rating)
Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.
- Get a free copy of the StockNews.com research report on Veru (VERU)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Now’s The Time To Buy Disney (NYSE: DIS)
- 3 Small Caps With Big Return Potential
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.